Amgen ends TScan partnership, Amylyx unveils $350M financing
Amgen is terminating its partnership with TScan Therapeutics, according to the latter. Amylyx has announced a $350 million offering. Additional updates cover BioArctic, Enveda, Georgiamune, Kynexis, Tolerance Bio, and Network Bio.
Related stories
Moderna raises $2B, while partners report Phase 3 successes · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Amgen cans its TScan partnership; Amylyx reveals $350M offering.” Browse more stories.